Skip to main content
SpringerLink
Log in
Book cover

Biological Basis of Geriatric Oncology pp 173–186Cite as

Biological Basis of the Association of Cancer and Aging Comorbidity

  • Chapter

Part of the book series: Cancer Treatment and Research ((CTAR,volume 124))

2. Conclusions

Comorbidity and its treatment appear to be an important influence on the behavior of cancer in older patients. Rather than a blanket effect, this may be attached to groups of syndromes with common pathophysiological mechanisms. In addition to paying attention to the impact of cancer treatment on comorbidity, or on the impact of comorbidity on the ability to deliver cancer treatment, we will have in the future to pay attention on the direct impact of comorbidity on the behavior of the cancer in elderly patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L: Comorbidity and functional status are independent in older cancer patients. Journal of Clinical Oncology 16:1582–7, 1998

    PubMed  CAS  Google Scholar 

  2. Extermann M, Yoder J, Overcash J, Wallace K, Vranas P, Braud AC, Luciani A, Carbonel A, Cantor AB: Influence of concomitant medications metabolized by cytochrome P-450 on toxicity from chemotherapy. 8th International Conference on Geriatric Oncology, Rome, Italy, Nov 21–22, 2003

    Google Scholar 

  3. Greenfield S, Blanco DM, Elashoff RM, Ganz PA: Patterns of care related to age of breast cancer patients. JAMA 1987 May 22–29; 257(20):2766–70

    Article  PubMed  CAS  Google Scholar 

  4. Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994 Jan 15; 120(2):104–10

    PubMed  CAS  Google Scholar 

  5. Newschaffer CJ, Bush TL, Penberthy LE, Bellantoni M, Helzlsour K, Diener-West M Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. J Gerontol A Biol Sci Med Sci. 1998 Sep; 53(5):M372–8

    PubMed  CAS  Google Scholar 

  6. Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, De Cataldis G, lannelli A, Bilancia D, Belli M, Massidda B, Piantedosi F, Comella G, De Lena M: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced nonsmall-cell lung cancer. J Clin Oncol. 2000 Jul; 18(13):2529–36

    PubMed  CAS  Google Scholar 

  7. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Third report of the national cholesterol education program (NCEP). Circulation 2002; 106:3143

    Google Scholar 

  8. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998 Jul; 15(7):539–53

    Article  PubMed  CAS  Google Scholar 

  9. Brauer PM, McKeown-Eyssen GE, Jazmaji V et al: Familial aggregation of diabetes and hypertension in a case-control study of colorectal neoplasia. Am J Epidemiol 156:702–713, 2002

    Article  PubMed  Google Scholar 

  10. Le Marchand L, Wilkens LR, Kolonel LN et al: Assocaitions of sedentary lifestyle, obesity, smoking, alcohol use and diabetes with the risk of colorectal cancer. Cancer Res 57:4787–94, 1997

    PubMed  Google Scholar 

  11. Hu FB, Manson JE, Liu S, et al: Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 91:542–7, 1999

    Article  PubMed  CAS  Google Scholar 

  12. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB III, Fuchs CS: Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003 Feb 1; 21(3):433–40

    Article  PubMed  Google Scholar 

  13. Little SA, Jarnagin WR, DeMatteo RP, Blumgart LH, Fong Y: Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer. J Gastrointest Surg 6:88–94, 2002

    Article  PubMed  Google Scholar 

  14. Weiss HA, Brinton LA, Potischman NA, Brogan D, Coates RJ, Gammon MD, Malone KE, Schoenberg JB: Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol. 1999 Oct; 28(5):816–23

    Article  PubMed  CAS  Google Scholar 

  15. Tavani A, La Vecchia C, Franceschi S, Serraino D, Carbone A: Medical history and risk of Hodgkin’s and non-Hodgkin’s lymphomas. Eur J Cancer Prev 9:59–64, 2000

    Article  PubMed  CAS  Google Scholar 

  16. Meyerhardt JA, Catalano PJ, Haller DG et al: Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 98:484–495, 2003

    Article  PubMed  Google Scholar 

  17. Marugame T, Lee K, Eguchi H, Oda T, Shinchi K, Kono S: Relation of impaired glucose tolerance and diabetes mellitus to colorectal adenomas in Japan. Cancer Causes Control 13:917–921, 2002

    Article  PubMed  Google Scholar 

  18. Komninou D, Ayonote A, Richie JP, Rigas B: Insulin resistance and its contribution to colon carcinogenesis. Exp Biol Med 228:396–405, 2003

    CAS  Google Scholar 

  19. Talvensaari KK, Lanning M, Tapanainen P, Knip M: Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab, 81:3051–5, 1996

    Article  PubMed  CAS  Google Scholar 

  20. Cohen HJ, Harris T, Pieper CF: Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med. 2003 Feb 15; 114(3):180–7

    Article  PubMed  Google Scholar 

  21. Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, Habermann TM: Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer. 2003 Sep 20; 106(5):784–8

    Article  PubMed  CAS  Google Scholar 

  22. Fryzek JP, Mellemkjaer L, McLaughlin JK, Blot WJ, Olsen JH: Cancer risk among patients with finger and hand joint and temporo-mandibular joint prostheses in Denmark. Int J Cancer 81:723–5, 1999

    Article  PubMed  CAS  Google Scholar 

  23. Coakley G, Brooks D, Iqbal M, et al: Major histocompability complex haplotypic associations with Felty’s syndrome and large granular lymphocyte syndrome are secondary to allelic association with HLA-DRB1*0401. Rheumatology 39:393–8, 2000

    Article  PubMed  CAS  Google Scholar 

  24. Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ: National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year follow-up study. J Rheumatol 2003 May; 30(5):958–65

    PubMed  Google Scholar 

  25. Collin P, Reunala T, Pukkala E et al: Coeliac disease-associated disorders and survival. Gut 35:1215–8, 1994

    PubMed  CAS  Google Scholar 

  26. Ioannidis JP, Vassiliou VA, Moutsopoulos HM: Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren’s syndrome. Arthritis Rheum. 2002 Mar; 46(3):741–7

    Article  PubMed  Google Scholar 

  27. De Re V, De Vita S, Gasparotto D et al: Salivary gland B-cell lymphoproliferative disorders in Sjören’s syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkin’s lymphomas. Eur J Immunol 32:903–910, 2002

    Article  PubMed  Google Scholar 

  28. Davidson BKS, Kelly CA, Griffiths ID: Primary Sjören’s syndrome in the North East of England: a long-term follow-up study. Rheumatology 38:245–253, 1999

    Article  PubMed  CAS  Google Scholar 

  29. Sultan SM, Ioannou Y, Isenberg DA: Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology (Oxford) 39:1147–52, 2000

    Article  PubMed  CAS  Google Scholar 

  30. Nived O, Bengtsson A, Jonsen A, Sturfelt G, Olsson H: Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus. 2001; 10(7):500–4

    CAS  Google Scholar 

  31. Mellemkjaer L, Andersen V, Linet MS et al: Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40:761–8, 1997

    PubMed  CAS  Google Scholar 

  32. Cibere J, Sibley J, Haga M: Systemic lupus erythematosus and the risk of malignancy. Lupus 10:394–400, 2001

    Article  PubMed  CAS  Google Scholar 

  33. Abu-Shakra M, Gladman DD, Urowitz MB: Malignancy in systemic lupus erythematosus. Arthritis Rheum 39:1050–4, 1996

    PubMed  CAS  Google Scholar 

  34. Ramsey-Goldman R, Mattai SA, Schilling E, et al: Increased risk of malignancy in patients with systemic lupus erythematosus. J. Investig Med 46:217–222, 1998

    PubMed  CAS  Google Scholar 

  35. Bateman H, Yacizi Y, Leff L, Peterson M, Paget SA: Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus 9:542–4, 2000

    PubMed  CAS  Google Scholar 

  36. Mariette X, Cazals-Hatem D, Warszawski J et al: Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99:3909–15, 2002

    Article  PubMed  CAS  Google Scholar 

  37. Kamel OW, Holly EA, van de Rijn M, Lele C, Sah A: A population based, case control study of non-Hodgkin’s lymphoma in patients with rheumatoid arthritis. J Rheumatol. 26:1676–80, 1999

    PubMed  CAS  Google Scholar 

  38. Fraser AG, Orchard TR, Robinson EM, Jewell DP: Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 16:1225–32, 2002

    Article  PubMed  CAS  Google Scholar 

  39. Smith KJ, Skelton HG: Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necorsis factor alpha receptor IgGl-Fc fusion complex therapy. J Am Acad Dermatol 45:953–6, 2001

    Article  PubMed  CAS  Google Scholar 

  40. Brown, SL, Greene MH, Gershon SK, Edwards ET, Braun MM: Tumor necrosis factor antagonist therapy and lymphoma development. Arthritis & Rheumatism 46:3151–8, 2002

    Article  CAS  Google Scholar 

  41. Schwartzenbaum J, Jonsson F, Ahlbom A et al: Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer 106:423–8, 2003

    Article  Google Scholar 

  42. Brenner AV, Linet MS, Fine HA et al: History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer 99:252–9, 2002

    Article  PubMed  CAS  Google Scholar 

  43. González-Pérez A, García Rodríguez LA, López-Ridaura R: Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and the rectum: a meta-analysis. BMC Cancer 3:28, 2003

    Article  PubMed  Google Scholar 

  44. Eaden J: Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 18(suppl 2):15–21, 2003

    Article  PubMed  CAS  Google Scholar 

  45. Rahme E, Barkun AN, Toubouti Y, Bardou M: The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 125:404–412, 2003

    Article  PubMed  CAS  Google Scholar 

  46. Sandler RS, Halabi S, Baron JA et al: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883–890, 2003

    Article  PubMed  CAS  Google Scholar 

  47. Baron JA, Cole BF, Sandler RS, et al: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891–899, 2003

    Article  PubMed  CAS  Google Scholar 

  48. Benamouzig R, Deyra J, Martin A et al: Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125:328–336, 2003

    Article  PubMed  CAS  Google Scholar 

  49. Steinbach G, Lynch PM, Phillips RK et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–52, 2000

    Article  PubMed  CAS  Google Scholar 

  50. Phillips RK, Wallace MH, Lynch PM, et al: A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut, 50:857–60, 2002

    Article  PubMed  CAS  Google Scholar 

  51. Giardello FM, Yang VW, Hylind LM et al: Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346:1054–9, 2002

    Article  Google Scholar 

  52. Khuder SA, Mutgi AB: Breast cancer and NSAID use: a meta-analysis. Br J Cancer. 2001 May 4; 84(9):1188–92

    Article  PubMed  CAS  Google Scholar 

  53. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A: Women’s Health Initiative. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res. 2003 Sep 15; 63(18):6096–101

    PubMed  CAS  Google Scholar 

  54. Kundu N, Fulton AM: Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 62:2343–6, 2002

    PubMed  CAS  Google Scholar 

  55. Elder DJ, Paraskeva C: Induced apoptosis in the prevention of colorectal cancer by non-steroidal anti-inflammatory drugs. Apoptosis 4:365–372, 1999

    Article  PubMed  CAS  Google Scholar 

  56. Rice PL, Kelloff J, Sullivan H et al: Sulindac induces caspase-and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2:885–892, 2003

    PubMed  CAS  Google Scholar 

  57. Howe LR, Subbaramiah K, Patel J et al: Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER2/neu)-induced breast cancer. Cancer res 62:5405–7, 2002

    PubMed  CAS  Google Scholar 

  58. Yasumaru M, Tsuji S, Tsujii M et al: Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Cancer Res 63:6726–6734, 2003

    PubMed  CAS  Google Scholar 

  59. Fenwick SW, Toogood GJ, Lodge JP, Hull MA: The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 125:716–729, 2003

    Article  PubMed  CAS  Google Scholar 

  60. O’Donoghue GT, Roche-Nagle G, Connolly EM et al: Selective COX-2 inhibition attenuates the perioperative increase of the tumour enhancing pro-angiogenic cytokine Vegf in human breast cancer patients. J Surg Res 114:243, 2003

    Article  Google Scholar 

  61. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI: Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002 May; 109(10):1321–6

    Article  PubMed  CAS  Google Scholar 

  62. Abou-Issa HM, Alshafie GA, Seibert K et al: Dose-response effects ot the COX-2 inhibitor, celecoxib, on the prevention of mammary carcinogenesis. Anticancer res 21:3425–32, 2001

    PubMed  CAS  Google Scholar 

  63. Sample D, Wargowich M, Fisher SM et al: A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev 11:275–9, 2002

    PubMed  CAS  Google Scholar 

  64. Mortimer JE: The protective effects of statins on the incidence of breast cancer in older women. 8th International Conference on Geriatric Oncology, Rome, Italy, Nov 21–22, 2003

    Google Scholar 

  65. Cauley JA, Zmuda JM, Lui LY et al: Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 12:749–756, 2003

    Article  Google Scholar 

  66. Graaf MR, Beiderbeck AB, Egberts ACG et al: The risk of cancer in statin users. Proc Am Soc Clin Oncol 22:846, 2003

    Google Scholar 

  67. Bjerre LM, LeLorier J: Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 110:716–723, 2001

    Article  PubMed  CAS  Google Scholar 

  68. Coogan PF, Rosenberg L, Palmer JR et al: Statin use and the risk of breast and prostate cancer. Epidemilogy 13:262–267, 2002

    Article  Google Scholar 

  69. Kaye JA, Meier CR, Walker AM, Jick H: Statin use, hyperlipidemia, and the risk of breast cancer. Br J Cancer 86:1436–9, 2002

    Article  PubMed  CAS  Google Scholar 

  70. Beck P, Wysowski DK, Downey W, Butler-Jones D: Statin use and the risk of breast cancer. J Clin Epidemiol 56:280–5, 2003

    Article  PubMed  Google Scholar 

  71. Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner M: Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol 2003 Sep; 31(9):779–83

    Article  PubMed  CAS  Google Scholar 

  72. Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn LZ: Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res. 2001 Jul; 7(7):2067–75

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Senior Adult Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

    Martine Extermann (Program Leader and Associate Professor of Oncology and Medicine)

  2. University of South Florida College of Medicine, Tampa, Florida

    Martine Extermann (Program Leader and Associate Professor of Oncology and Medicine)

Authors
  1. Martine Extermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of South Florida College of Medicine, Tampa, Florida, USA

    Lodovico Balducci MD (Professor of Oncology and Medicine and Program Leader) & Martine Extermann MD, PhD (Associate Professor of Oncology and Medicine) (Professor of Oncology and Medicine and Program Leader) &  (Associate Professor of Oncology and Medicine)

  2. Senior Adult Oncology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA

    Lodovico Balducci MD (Professor of Oncology and Medicine and Program Leader) & Martine Extermann MD, PhD (Associate Professor of Oncology and Medicine) (Professor of Oncology and Medicine and Program Leader) &  (Associate Professor of Oncology and Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science + Business Media, Inc.

About this chapter

Cite this chapter

Extermann, M. (2005). Biological Basis of the Association of Cancer and Aging Comorbidity. In: Balducci, L., Extermann, M. (eds) Biological Basis of Geriatric Oncology. Cancer Treatment and Research, vol 124. Springer, Boston, MA. https://doi.org/10.1007/0-387-23962-6_9

Download citation

  • DOI: https://doi.org/10.1007/0-387-23962-6_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-23961-3

  • Online ISBN: 978-0-387-23962-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation